Saad Usmani: ASH 2026 Highlights Emerging Immunotherapy Strategies in Multiple Myeloma
Saad Usmani/X

Saad Usmani: ASH 2026 Highlights Emerging Immunotherapy Strategies in Multiple Myeloma

Saad Usmani, Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and Professor of Clinical Medicine at Weill Cornell Medical College, shared on X: 

“The Best of ASH 2026 – Multiple Myeloma: Final Thoughts

Three themes stand out:

  • Earlier immunotherapy: T-cell redirecting therapies are moving into frontline and earlier relapse settings.
  • Next-generation immune targeting: Dual-antigen CAR-T, multiplexed T-cell engagers and sequential immune therapies are expanding our therapeutic possibilities.
  • Precision myeloma medicine: Genomics, antigen expression and mechanisms of resistance may increasingly guide treatment selection and sequencing.

The challenge ahead is translating deeper responses into durable disease control, improved survival and ultimately functional cure.

Exciting times for the myeloma community! “

Saad Usmani: ASH 2026 Highlights Emerging Immunotherapy Strategies in Multiple Myeloma

About Emerging Multiple Myeloma Therapies at ASH 2026

The 68th American Society of Hematology (ASH) Annual Meeting, scheduled for December 12–15, 2026, in New Orleans, will highlight advances in hematologic malignancies, including emerging treatment approaches for multiple myeloma. Scientific abstracts were released on November 4, providing an early look at research scheduled for presentation.

One important development in multiple myeloma is the expanding role of T-cell redirecting immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies. Initially used primarily in heavily pretreated patients, these approaches are increasingly being evaluated in earlier lines of therapy.

Read more here.